BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit
January 21 2020 - 9:53AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading
developer of adult stem cell therapeutics for neurodegenerative
diseases, announced today that Ralph Kern, MD, MHSc, Chief
Operating Officer and Chief Medical Officer, will present at the
10th Annual California ALS Research Summit, January 24-25 at
Cedars-Sinai Medical Center, Los Angeles, California.
Dr. Kern will provide an update on BrainStorm’s
Phase 3 ALS Clinical Trial on Friday, January 24, 10:30 -11:10 AM
PT, during the session: “CIRM funded Stem Cell Clinical Trials in
California – Updates.”
Dr. Kern stated, “This prestigious Summit works
to increase, expedite and promote the amount and level of
amyotrophic lateral sclerosis (ALS) research done in California
that has been reinforced and amplified by the international ALS
scientific and medical community. I am pleased to have the
opportunity to share all that BrainStorm has accomplished in our
fully enrolled Phase 3 clinical trial of
NurOwn® (NCT03280056).”
Chaim Lebovits, President and CEO of BrainStorm,
stated, “California continues to be a global leader in stem cell
research and scientific funding. Due to California’s commitment to
stem cell scientific investigation, BrainStorm is at an inflection
point as we bring our investigational therapy, NurOwn, toward the
submission of a biological license application. In July 2017,
BrainStorm was awarded a grant of $15.9 million from the California
Institute for Regenerative Medicine (CIRM) and three of
California’s most prestigious medical centers: University of
California, Irvine, Cedars-Sinai Medical Center, and California
Pacific Medical Center have contributed immensely to advancement of
NurOwn. Everyone at BrainStorm is proud Dr. Kern will have the
opportunity to present to the ALS community of California all that
has been accomplished due to their ongoing support and
encouragement.”
About The California ALS Research
Summit:
The California ALS Research Summit is the tenth
annual gathering of researchers, investigators, clinicians, biotech
companies, government representatives, partner organizations, and
advocates in ALS and related fields in the State of California.
The purpose of the Summit is to help increase,
expedite and promote the amount and level of amyotrophic lateral
sclerosis (ALS, also known as Lou Gehrig's Disease) and related
research done in California; and to foster networking,
collaboration and cooperation among investigators, their peers and
their colleagues to identify, develop and deliver new and effective
treatments, ideas and, ultimately, cures for ALS.
The result of our efforts is an ongoing roadmap
for ALS research in California, which will provide the basis for
partnering within the state and other supporters to further studies
to find new treatments and ultimately a cure for the
disease.
About NurOwn®
NurOwn® (autologous MSC-NTF cells) represent a
promising investigational approach to targeting disease pathways
important in neurodegenerative disorders. MSC-NTF cells are
produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. NurOwn® is
currently being evaluated in a Phase 3 ALS randomized
placebo-controlled trial and in a Phase 2 open-label multicenter
trial in Progressive MS.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. For more information, visit BrainStorm's
website at www.brainstorm-cell.com.
Safe-Harbor
Statement
Statements in this announcement other than
historical data and information, including statements regarding
future clinical trial enrollment and data, constitute
"forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics
Inc.'s actual results to differ materially from those stated
or implied by such forward-looking statements. Terms and phrases
such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",
and similar terms and phrases are intended to identify these
forward-looking statements. The potential risks and uncertainties
include, without limitation, BrainStorm’s need to raise additional
capital, BrainStorm’s ability to continue as a going concern,
regulatory approval of BrainStorm’s NurOwn® treatment candidate,
the success of BrainStorm’s product development programs and
research, regulatory and personnel issues, development of a global
market for our services, the ability to secure and maintain
research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm’s
NurOwn® treatment candidate to achieve broad acceptance as a
treatment option for ALS or other neurodegenerative diseases,
BrainStorm’s ability to manufacture and commercialize the NurOwn®
treatment candidate, obtaining patents that provide meaningful
protection, competition and market developments, BrainStorm’s
ability to protect our intellectual property from infringement by
third parties, heath reform legislation, demand for our services,
currency exchange rates and product liability claims and
litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS
Corporate: Uri Yablonka Chief
Business Officer BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188 uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR PR Phone:
+1.646.677.1839 sean.leous@icrinc.com
Or:Katie GallagherLaVoieHealthSciencesPhone: +
1 617-374-8800 x109kgallagher@lavoiehealthscience.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Sep 2023 to Sep 2024